MDM2 overexpression is also associated with metastasis and advanced stages of cancers such as osteosarcoma, colon, breast, and prostate cancers, and has been linked to chemotherapy resistance (Lin et al., 2024[123]). Here, MDM2 is linked to prostate carcinoma.